1. Home
  2. BOLT vs CWD Comparison

BOLT vs CWD Comparison

Compare BOLT & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$5.30

Market Cap

10.5M

Sector

Health Care

ML Signal

HOLD

Logo CaliberCos Inc.

CWD

CaliberCos Inc.

HOLD

Current Price

$1.58

Market Cap

10.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
BOLT
CWD
Founded
2015
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
10.5M
10.8M
IPO Year
2021
2023

Fundamental Metrics

Financial Performance
Metric
BOLT
CWD
Price
$5.30
$1.58
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$34.00
N/A
AVG Volume (30 Days)
31.5K
160.8K
Earning Date
11-12-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,195,000.00
$24,657,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$26.79
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.41
$1.42
52 Week High
$12.60
$48.00

Technical Indicators

Market Signals
Indicator
BOLT
CWD
Relative Strength Index (RSI) 49.12 33.04
Support Level $5.09 $1.42
Resistance Level $5.71 $1.83
Average True Range (ATR) 0.39 0.11
MACD -0.02 0.03
Stochastic Oscillator 23.48 34.74

Price Performance

Historical Comparison
BOLT
CWD

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.

About CWD CaliberCos Inc.

CaliberCos Inc is an asset management firm whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. The majority of revenue is derived from the fund management fees segment.

Share on Social Networks: